Zimmer Biomet shows steady sales growth amid transformation and debt challenges

Zimmer Biomet is experiencing steady sales growth driven by transformation efforts, research and development, and mergers and acquisitions. However, earnings growth has been slower to catch up with sales. This growth is important as the company manages a significant debt load, with potential for stock re-rating if earnings improve. Shares have rebounded to around $100 after dipping to the mid-$80s earlier in the year.